Switzerland-based Nouscom AG has named Tiffany Muller as chief financial officer and Loredana Siani as head of chemistry, manufacturing and controls (CMC) as it advances its cancer vaccine portfolio into late-stage clinical development. Nouscom is developing allogeneic cancer immunotherapies delivered to the body in viral vectors encoded with neoantigens. Its lead product is being tested in Phase 2 for solid tumours.
Ms Muller is being promoted to the position of CFO having previously been vice president for finance. She holds bachelor and master’s degrees in mathematics respectively from Bryn Mawr College and Villanova University and will be based in the US. Dr Siani, who holds a PhD in industrial biotechnology science from the University Federico II in Naples, Italy, has been named senior vice president, technical and CMC development.
Copyright 2024 Evernow Publishing Ltd